Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Aims: With the current focus on lipoprotein(a) as a likely causal risk factor for cardiovascular disease and new drugs potentially on the market to lower lipoprotein(a) levels, the safety of lowering lipoprotein(a) to low levels becomes increasingly important. We tested whether low levels of lipoprotein(a) and corresponding LPA genotypes associate with major disease groups including cancers and infectious disease. Methods and results: We included 109 440 individuals from the Copenhagen General Population Study. For main World Health Organization International Classification of Diseases 10th edition chapter diseases, the only concordant association of low levels of lipoprotein(a) plasma levels and corresponding LPA genotypes with risk of disease was with low risk of diseases of the circulatory system. Furthermore, no concordant association of low levels of lipoprotein(a) plasma levels and corresponding LPA genotypes with the risk of any cancer (i.e. cancer subtypes combined) or infectious disease was seen. The hazard ratio for the risk of any cancer was 1.06 [95% confidence interval (CI): 0.97–1.15] for the first vs. the fourth quartile of lipoprotein(a), 1.02 (0.97–1.07) for the fourth vs. the first quartile of KIV-2 number of repeats, and 1.01 (0.96–1.07) for rs10455872 non-carriers vs. carriers. The corresponding hazard ratios for the risk of hospitalization for infection were 1.05 (95% CI: 0.99–1.10), 1.02 (0.98–1.07), and 0.97 (0.93–1.03), respectively. Conclusion: In a large, contemporary, general population cohort, apart from the well-established association with cardiovascular disease, low levels of lipoprotein(a) and corresponding LPA genotypes did not concordantly associate with any major disease groups including cancers and infections. There is no safety signal from our results to indicate that low levels of lipoprotein(a) are harmful.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [187]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Self-citationMendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Self-citationGenetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Self-citation
Cited by
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
“and Langsted et al.(138) studies; Supplementary material online, Figure S1A) or when excluding the case–control study by Gudbjartsson et al.”
BackgroundSelf-citationLipoprotein(a) and cardiovascular disease
Nordestgaard, B. G., & Langsted, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01308-4 · Cited by 288
Self-citationCoassin, S., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.003 · Cited by 219
“[46,55], LPA is a clear early candidate for the therapeutic intervention using somatic gene editing [56].”
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
Arsenault, B. J., & Kamstrup, P. R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.015 · Cited by 132
Self-citationLipoprotein (a) and diabetes mellitus
Lamina, C., & Ward, N. C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.016 · Cited by 120
Metadata
- Authors
- Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Corresponding author
- Kamstrup, Pia R
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-01-22
- Volume
- 42
- Issue
- 12
- Pages
- 1147-1156
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3136144822
- Cited by
- 72
- References
- 39
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 14 · 2022: 17 · 2021: 8
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Medical Research Council
- Danish Heart Foundation
- Copenhagen County Foundation
- Herlev and Gentofte Hospital
- Copenhagen University Hospital
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- lipoprotein(a), LPA gene, rs10455872, cardiovascular disease, cancer risk, infectious diseases, hospitalization, drug safety, Copenhagen General Population Study
- MeSH terms
- Cardiovascular Diseases, Genotype, Humans, Risk Factors, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa1085
- The paper
- Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R. (2021). Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa1085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.